PAB 25.0% 0.3¢ patrys limited

data from 1st cohort of patients in multiple m

  1. 1,670 Posts.
    First date in.

    Data from 1st Cohort of Patients in Multiple Myeloma Clinical Trial
    ? First cohort of patients treated with multiple doses of PAT-SM6 in multiple myeloma clinical trial; no serious adverse events reported
    ? Early evidence that PAT-SM6 is active in patients with resistant, end-stage disease
    ? Second cohort of patients currently being recruited
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.